Brain tumour immunology and therapy group

Main content

Our mission is to develop a new treatment that can be tested in clinical trials for GBM patients and that can be used in combination with standard treatment regimens to improve the quality of life and extend survival of GBM patients.

Our goals are to:

(a) Investigate the mechanisms of NG2 mediated treatment resistance and poor outcome in GBM patients based on identification of interacting targets through genomic and proteomic analyses in patient biological samples and functional validation in cellular and animal models.

(b) Develop new molecular and immunotherapy strategies targeting the NG2 proteoglycan in glioblastoma.

(c) To characterise the immunological phenotype and function of GBM patients in order to determine feasibility and strategy of future immunotherapy.